# SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

> **NCT03546582** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **RTOG Foundation, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC)

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT03546582
- **Lead sponsor:** RTOG Foundation, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-14
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546582, "SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03546582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*